Suppr超能文献

肝素和类肝素可阻止含核小体抗原的免疫复合物与肾小球基底膜结合,并延缓MRL/lpr小鼠的肾炎进程。

Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice.

作者信息

van Bruggen M C, Walgreen B, Rijke T P, Corsius M J, Assmann K J, Smeenk R J, van Dedem G W, Kramers K, Berden J H

机构信息

Department of Pathology, University Hospital Nijmegen, The Netherlands.

出版信息

Kidney Int. 1996 Nov;50(5):1555-64. doi: 10.1038/ki.1996.471.

Abstract

Monoclonal anti-nucleosome antibodies (mAbs) complexed to nucleosomal antigens can bind to DNA and to heparan sulfate (HS) in ELISA and to the GBM in vivo in a rat renal perfusion system, whereas non-complexed mAbs do not bind [1]. In this study, we analyzed whether heparin (HEP) or N-desulfated/acetylated heparins (DSA-HEP), structurally and functionally strongly related to HS, are able to prevent the binding of these complexed mAbs to DNA and to HS in vitro and to rat GBM in vivo. In ELISA the binding of nucleosome complexed antinucleosome antibodies to DNA and HS was inhibited dose-dependently by HEP, DSA-HEP and low molecular weight (LMW) DSA-HEP. Intravenous injection of nucleosome/anti-nucleosome immune complexes without heparin/heparinoids in BALB/c mice led to GBM binding, while simultaneous injection of heparin/heparinoids with complexed antibodies or pretreatment with heparin subcutaneously prior to injection of complexes prevented this binding. Subsequently, we tested the preventive effect of HEP, DSA-HEP and LMW-DSA-HEP on progression of renal disease in MRL/lpr mice. Treatment was started at an age of eight weeks in a dose of 50 micrograms daily. With all three drugs albuminuria was significantly delayed compared to PBS treated controls (cumulative incidence of proteinuria at 20 weeks in controls 60% vs. 13%, 14% and 6% respectively for HEP, DSA-HEP and LMW-DSA-HEP; P < 0.05). At week 21 the glomerulonephritis was histologically less severe in heparin/heparinoid treated animals (P = 0.02). In immunofluorescence the amount of immunoglobulin and C3 deposits in the glomerular capillary wall tended to be less in heparin/heparinoid treated mice compared to PBS treated controls (P = 0.07). Furthermore, at 20 weeks anti-HS levels in plasma of heparin/heparinoid treated mice were significantly lower (P < 0.05). We conclude that interaction of heparin or heparin analogs with HS reactive immune complexes containing nucleosomal antigens prevents the binding of these immune complexes to the GBM and delays nephritis in MRL/lpr mice.

摘要

与核小体抗原复合的单克隆抗核小体抗体(mAb)在酶联免疫吸附测定(ELISA)中可与DNA及硫酸乙酰肝素(HS)结合,在大鼠肾脏灌注系统中可在体内与肾小球基底膜(GBM)结合,而非复合的mAb则不结合[1]。在本研究中,我们分析了与HS在结构和功能上密切相关的肝素(HEP)或N - 去硫酸化/乙酰化肝素(DSA - HEP)是否能够在体外阻止这些复合的mAb与DNA及HS结合,以及在体内阻止其与大鼠GBM结合。在ELISA中,HEP、DSA - HEP和低分子量(LMW)DSA - HEP对核小体复合抗核小体抗体与DNA及HS的结合具有剂量依赖性抑制作用。在BALB/c小鼠中静脉注射不含肝素/类肝素的核小体/抗核小体免疫复合物会导致GBM结合,而在注射复合物时同时注射肝素/类肝素或在注射复合物前皮下注射肝素进行预处理可阻止这种结合。随后,我们测试了HEP、DSA - HEP和LMW - DSA - HEP对MRL/lpr小鼠肾脏疾病进展的预防作用。在八周龄时开始治疗,每日剂量为50微克。与用磷酸盐缓冲盐水(PBS)处理的对照组相比,使用这三种药物均显著延迟了蛋白尿的出现(对照组20周时蛋白尿的累积发生率为60%,而HEP、DSA - HEP和LMW - DSA - HEP组分别为13%、14%和6%;P < 0.05)。在第21周时,肝素/类肝素处理的动物组织学上肾小球肾炎的严重程度较轻(P = 0.02)。在免疫荧光检查中,与PBS处理的对照组相比,肝素/类肝素处理的小鼠肾小球毛细血管壁中免疫球蛋白和C3沉积物的量趋于减少(P = 0.07)。此外,在20周时,肝素/类肝素处理的小鼠血浆中抗HS水平显著降低(P < 0.05)。我们得出结论,肝素或肝素类似物与含有核小体抗原的HS反应性免疫复合物的相互作用可阻止这些免疫复合物与GBM结合,并延缓MRL/lpr小鼠的肾炎进程。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验